At Bio Design Lab, we redefine the development of biopharmaceuticals through our innovative systems-level genetic and genomic design-based strategies. Unlike conventional methods that modify single components of complex bio-entities—often resulting in unforeseen serious side effects—we view biopharmaceuticals as intricate systems with interconnected biomolecular components.

RetroNext and LentiNext are advanced viral vector platforms that significantly enhance the safety and efficiency of gene therapy compared to traditional retroviral and lentiviral vectors. Retroviruses and lentiviruses are commonly used in gene therapy clinical trials due to their ability to integrate therapeutic genes into the host cell genome, resulting in long-term expression and a lower immune response compared to Adeno-Associated Virus (AAV). This feature allows for the delivery of large therapeutic payloads. Despite these advantages, the use of traditional retro and lentiviral vectors has declined due to safety concerns, including potential oncogenesis triggered by their inherent insertion patterns. BioDesign Lab has utilized cutting-edge genetic engineering and systems biology to develop RetroNext and LentiNext, which dramatically improve safety and efficiency. These platforms have shown significantly safer insertion patterns with over 90% reduction in insertions into risk-prone areas, minimizing the risks of cancer and other adverse effects. RetroNext and LentiNext are not only suited for gene therapies but also applicable to targeted cancer therapies such as CAR-T and CAR-NK cells. They can also serve as delivery platforms for the emerging gene-editing technology, CRISPR-CAS9. This versatility opens up multiple avenues for commercialization in various therapeutic areas.

Private

etc